Table I.
Summary of lenalidomide-induced drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) cases
| Primary disease | Age, years/Sex | Medical history | Time intervala | HHV-6 reactivation | DiHS criteria | DRESS criteria (score) | Treatment | Reference |
|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | 78/F | Hypertension, diabetes mellitus | 4 weeks | Positive | Typical 7/7 | Definite (7) | PSL 20 mg/day | (4) |
| Multiple myeloma | 65/F | Acute interstitial nephritis | 4 weeks | Negative | Atypical 5/7 | Definite (7) | PSL 80 mg/day | (5) |
| Multiple myeloma | 62/F | Chronic kidney disease | 5 days | N.D. | Atypical 5/7 | Probable (5) | PSL | (6) |
| Multiple myeloma | 75/F | Hypertension, diabetes mellitus | 4 weeks | N.D. | Atypical 6/7 | Definite (7) | mPSL 80 mg/day | (7) |
| Multiple myeloma | 59/M | Hypertension, Hyperuricemia | 5 weeks | Positive | Typical 7/7 | Definite (7) | PSL 20 mg/day | Current case |
a
The period before the onset of rash after lenalidomide administration.
HHV-6: human herpes virus-6; mPSL: methylprednisolone; N.D.: no description; PSL: prednisolone.